CYP2C9*3 allelic variant and bleeding complications

被引：65

作者：

Ogg, MS

Brennan, P

Meade, T

Humphries, SE ^{[1
]}

机构：

[1] UCL, London WC1E 6JJ, England

[2] St Bartholomews Sch Med, Wolfson Inst Prevent Med, MRC, Epidemiol & Med Care Unit, London, England

[3] Royal London Sch Med, Wolfson Inst Prevent Med, MRC, Epidemiol & Med Care Unit, London, England

来源：

LANCET | 1999年 / 354卷 / 9184期

关键词：

D O I：

10.1016/S0140-6736(05)76918-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1124 / 1124

页数：1

相关论文

共 5 条

[1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
[J]. LANCET, 1999, 353 (9154) : 717 - 719
[2] DAY INM, 1995, BIOTECHNIQUES, V19, P830
[3] RANDOMIZED CONTROLLED TRIAL OF LOW-DOSE WARFARIN IN THE PRIMARY PREVENTION OF ISCHEMIC HEART-DISEASE IN MEN AT HIGH-RISK - DESIGN AND PILOT-STUDY
MEADE, TW
WILKES, HC
STIRLING, Y
BRENNAN, PJ
KELLEHER, C
BROWNE, W
[J]. EUROPEAN HEART JOURNAL, 1988, 9 (08) : 836 - 843
[4] Meade TW, 1998, LANCET, V351, P233
[5] Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Steward, DJ
Haining, RL
Henne, KR
Davis, G
Rushmore, TH
Trager, WF
Rettie, AE
[J]. PHARMACOGENETICS, 1997, 7 (05): : 361 - 367